Researchers have demonstrated that a combination treatment of nicotinamide mononucleotide (NMN) and apigenin, referred to as N + A, significantly enhances cellular function and health in aged wild-type mice. This dual approach not only boosts NAD+ levels but also mitigates its depletion by inhibiting the enzyme CD38, which is known to increase with age. The study reveals that administering N + A restores muscle function and bone structure, effectively addressing age-related declines in musculoskeletal and gut health.

The significance of these findings lies in their potential for clinical application. Previous studies have established the benefits of NAD+ precursors like NMN and nicotinamide riboside (NR) in various contexts, such as improving insulin sensitivity and reducing inflammation. This new research builds on that foundation, showing that the combination of NMN and apigenin not only restores NAD+ levels to near-normal in senescent cells but also reduces inflammation and DNA damage. Notably, the treatment improved mitochondrial function and promoted differentiation in muscle, cartilage, and bone precursor cells, indicating a broad therapeutic potential.

The implications for the field are substantial. This study shifts the paradigm towards a combination therapy approach in aging research, emphasizing the importance of both supplying and preserving NAD+. The findings suggest that N + A could serve as a promising candidate for future clinical trials aimed at restoring musculoskeletal and gut health in older populations. As researchers move towards larger animal models and eventually human trials, this combination treatment could pave the way for innovative strategies in combating age-related degeneration and enhancing healthspan.

Source: lifespan.io